Browse > Article
http://dx.doi.org/10.5352/JLS.2014.24.6.700

Inhibition of Migration and Invasion of LNCap Human Prostate Carcinoma Cells by Doxorubicin through Inhibition of Matrix Metalloproteinase Activity and Tightening of Tight Junctions  

Choi, Yung Hyun (Department of Biochemistry, Dongeui University College of Oriental Medicine, Anti-Aging Research Center & Blue-Bio Industry RIC, Dongeui University)
Shin, Dong Yeok (Dongnam Institute of Radiological & Medicine Sciences)
Kim, Wun-Jae (Department of Urology, Chungbuk National University College of Medicine)
Publication Information
Journal of Life Science / v.24, no.6, 2014 , pp. 700-706 More about this Journal
Abstract
Doxorubicin (trade name adriamycin), an anthracycline antibiotic, is commonly used in the treatment of a wide range of cancers, including hematological malignancies, many types of carcinoma, and soft tissue sarcomas. It is closely related to the natural product daunomycin, and like all anthracyclines, it works by intercalating DNA. Its most serious adverse effect is life-threatening heart damage. Its anti-metastatic mechanisms in human prostate carcinomas are not fully understood. In this study, we used LNCap human prostate carcinoma cells to investigate the inhibitory effects of doxorubicin on cell motility and invasion, two critical cellular processes that are often deregulated during metastasis. Doxorubicin treatment inhibited cell migration and invasiveness of LNCap cells without showing any toxicity. Doxorubicin treatment also suppressed the activity and expression of matrix metalloproteinase (MMP)-2 and MMP-9, which were associated with up-regulated expression of tissue inhibitor of metalloproteinase (TIMP)-1 and TIMP-2 in LNCap cells. Doxorubicin treatment also attenuated the expression levels of claudin family members (claudin-1, -2,-3 and -4), major components of tightening of tight junctions (TJs) and increased the tightening of TJs, as demonstrated by an increase in transepithelial electrical resistance. The present findings demonstrate that doxorubicin reduces the migration and invasion of prostate carcinomas LNCap cells by modulating the activity of TJs and MMPs.
Keywords
Claudin; doxorubicin; invasion; matrix metalloproteinase (MMP); tight junctions;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Hutchinson, C. R. 1995. Anthracyclines. Biotechnology 128, 331-357.
2 John, A. and Tuszynski, G. 2001. The role of matrix metalloproteinases in tumor angiogenesis and tumor metastasis. Pathol Oncol Res 7, 14-23.   DOI   ScienceOn
3 Lal, S., Mahajan, A., Chen, W. N. and Chowbay, B. 2010. Pharmacogenetics of target genes across doxorubicin disposition pathway: a review. Curr Drug Metab 11, 115-128.   DOI
4 Lambert, E., Dasse, E., Haye, B. and Petitfrere, E. 2004. TIMPs as multifacial proteins. Crit Rev Oncol Hematol 49, 187-198.   DOI   ScienceOn
5 Lin, X., Shang, X., Manorek, G. and Howell, S. B. 2013. Regulation of the epithelial-mesenchymal transition by claudin-3 and claudin-4. PLoSOne 8, e67496.   DOI
6 Liu, Y., Miao, Y., Wang, J., Lin, X., Wang, L., Xu, H. T. and Wang, E. H. 2013. DEC1 is positively associated with the malignant phenotype of invasive breast cancers and negatively correlated with the expression of claudin-1. Int J Mol Med 31, 855-860.
7 Agarwal, R., D'Souza, T. and Morin, P. J. 2005. Claudin-3 and claudin-4 expression in ovarian epithelial cells enhances invasion and is associated with increased matrix metalloproteinase-2 activity. Cancer Res 65, 7378-7385.   DOI   ScienceOn
8 Angelow, S. and Yu, A. S. 2007. Claudins and paracellular transport: an update. Curr Opin Nephrol Hypertens 16, 459-464.   DOI   ScienceOn
9 Gibbs, D. F., Warner, R. L., Weiss, S. J., Johnson, K. J. and Varani, J. 1999. Characterization of matrix metalloproteinases produced by rat alveolar macrophages. Am J Respir Cell Mol Biol 20, 1136-1144.   DOI   ScienceOn
10 Weber, T. G., Pöschinger, T., Galbán, S., Rehemtulla, A. and Scheuer, W. 2013. Noninvasive monitoring of pharmacodynamics and kinetics of a death receptor 5 antibody and its enhanced apoptosis induction in sequential application with Doxorubicin. Neoplasia 15, 863-874.   DOI
11 Yoon, C. H., Kim, M. J., Park, M. J., Park, I. C., Hwang, S. G., An, S., Choi, Y. H., Yoon, G. and Lee, S. J. 2010. Claudin-1 acts through c-Abl-protein kinase Cdelta (PKCd) signaling and has a causal role in the acquisition of invasive capacity in human liver cells. J Biol Chem 285, 226-233.   DOI   ScienceOn
12 Zuryn, A., Litwiniec, A., Gackowska, L., Pawlik, A., Grzanka, A. A. and Grzanka, A. 2012. Expression of cyclin A, B1 and D1 after induction of cell cycle arrest in the Jurkat cell line exposed to doxorubicin. Cell Biol Int 36, 1129-1135.   DOI
13 Rangel, L. B., Agarwal, R., D'Souza, T., Pizer, E. S., Alò, P. L., Lancaster, W. D., Gregoire, L., Schwartz, D. R., Cho, K. R. and Morin, P. J. 2003. Tight junction proteins claudin-3 and claudin-4 are frequently overexpressed in ovarian cancer but not in ovarian cystadenomas. Clin Cancer Res 9, 2567-2575.
14 Minisini, A. M., Andreetta, C., Fasola, G. and Puglisi, F. 2008. Pegylated liposomal doxorubicin in elderly patients with metastatic breast cancer. Expert Rev Anticancer Ther 8, 331-342.   DOI
15 Mook, O. R., Frederiks, W. M. and Van Noorden, C. J. 2004. The role of gelatinases in colorectal cancer progression and metastasis. Biochim Biophys Acta 1705, 69-89.
16 Morin, P. J. 2005. Claudin proteins in human cancer: promising new targets for diagnosis and therapy. Cancer Res 65, 9603-9606.   DOI   ScienceOn
17 Uzui, H., Harpf, A., Liu, M., Doherty, T. M., Shukla, A. and Chai, N. 2002. Increased expression of membrane type 3-matrix metalloproteinase in human atherosclerotic plaque: role of activated macrophages and inflammatory cytokines. Circulation 106, 3024-3030.   DOI   ScienceOn
18 Vihinen, P., Ala-aho, R. and Kahari, V. M. 2005. Matrix metalloproteinases as therapeutic targets in cancer. Curr Cancer Drug Targets 5, 203-220.   DOI   ScienceOn
19 Turksen, K. and Troy, T. C. 2011. Junctions gone bad: claudins and loss of the barrier in cancer. Biochim Biophys Acta 1816, 73-79.
20 Utech, M., Bruwer, M. and Nusrat, A. 2006. Tight junctions and cell-cell interactions. Methods Mol Biol 341, 185-195.
21 Wang, Z., Yu, Y., Dai, W., Lu, J., Cui, J., Wu, H., Yuan, L., Zhang, H., Wang, X., Wang, J., Zhang, X. and Zhang, Q. 2012. The use of a tumor metastasis targeting peptide to deliver doxorubicin-containing liposomes to highly metastatic cancer. Biomaterials 33, 8451-8460.   DOI
22 Singh, A. B., Sharma, A. and Dhawan, P. 2010. Claudin family of proteins and cancer: an overview. J Oncol 2010, 541957.
23 Rathos, M. J., Khanwalkar, H., Joshi, K., Manohar, S. M. and Joshi, K. S. 2013. Potentiation of in vitro and in vivo antitumor efficacy of doxorubicin by cyclin-dependent kinase inhibitor P276-00 in human non-small cell lung cancer cells. BMC Cancer 13, 29.   DOI
24 Schneeberger, E. E. and Lynch, R. D. 2004. The tight junction: a multifunctional complex. Am J Physiol Cell Physiol 286, C1213-1228.   DOI   ScienceOn
25 Shang, X., Lin, X., Alvarez, E., Manorek, G. and Howell, S. B. 2012. Tight junction proteins claudin-3 and claudin-4 control tumor growth and metastases. Neoplasia 14, 974-985.   DOI
26 Soler, A. P., Miller, R. D., Laughlin, K. V., Carp, N. Z., Klurfeld, D. M. and Mullin, J. M. 1999. Increased tight junctional permeability is associated with the development of colon cancer. Carcinogenesis 20, 1425-1431.   DOI   ScienceOn
27 Huang, J., Yang, J., Maity, B., Mayuzumi, D. and Fisher, R. A. 2011. Regulator of G protein signaling 6 mediates doxorubicin- induced ATM and p53 activation by a reactive oxygen species-dependent mechanism. Cancer Res 71, 6310-6319.   DOI
28 Hutchinson, C. R. and Colombo, A. L. 1999. Genetic engineering of doxorubicin production in Streptomyces peucetius: a review. J Ind Microbiol Biotechnol 23, 647-652.   DOI   ScienceOn
29 Grant-Tschudy, K. S. and Wira, C. R. 2005. Effect of oestradiol on mouse uterine epithelial cell tumour necrosis factor- alpha release is mediated through uterine stromal cells. Immunology 115, 99-107.   DOI   ScienceOn
30 Grenader, T., Goldberg, A., Hadas-Halperin, I. and Gabizon, A. 2009. Long-term response to pegylated liposomal doxorubicin in patients with metastatic soft tissue sarcomas. Anticancer Drugs 20, 15-20.   DOI